MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Olfactory dysfunction"

  • 2022 International Congress

    Melatonin attenuates the bidirectional Gut-Brain axis mediated inflammation caused by Ambient Particulate Matter (PM2.5) and averts neurodegeneration

    SAM. Panda, VGM. Naidu (Guwahati, India)

    Objective: To explore the therapeutic potential of melatonin in attenuating the PM2.5 induced inflammation and neurodegeneration through the Gut-brain axis in C57BL/6 mice. Background: The…
  • 2022 International Congress

    CORRELATION BETWEEN OLFACTORY DYSFUNCTION AND INTENSITY OF TREMOR

    D D. Pokhabov, V. Abramov, M. Sadovsky, D V. Pokhabov (Krasnoyarsk, Russian Federation)

    Objective: Our aim was to obtain tremor data of PD and ET patients and the results of their olfactory function, which can help verify our…
  • 2022 International Congress

    Patients with Parkinson’s Disease Share a Unique Olfactory Perceptual Fingerprint

    M. Andelman-Gur, K. Snitz, A. Ravia, N. Hezi, A. Ezra, D. Klepikov, T. Gurevich, N. Sobel (Rehovot, Israel)

    Objective: To explore potential olfactory biomarkers for early detection of Parkinson's disease Background: Although the olfactory decline in Parkinson’s disease (PD) precedes the motor symptoms…
  • 2022 International Congress

    Olfactory Network Reorganization in Parkinson’s Disease

    L. Pesantez Pacheco, M. Saqib, D. Ehrlich, M. Hallett, S. Horovitz (Bethesda, USA)

    Objective: To explore changes in the organization and functionality of the olfactory network in patients with Parkinson’s Disease (PD) using graph theory-based network analysis on…
  • 2022 International Congress

    Olfactory dysfunction in patients with Huntington disease

    J. Patino, H. Coco, S. Zadegan, S. Chandra, N. Karagas, N. Rocha, K. Anderson, A. Teixeira, E. Furr Stimming (Houston, USA)

    Objective: To investigate olfactory dysfunction (OD) in individuals with Huntington disease (HD) and its relation to disease severity. Background: HD is a hereditary neurodegenerative disease…
  • MDS Virtual Congress 2021

    Serial olfactory testing for the diagnosis of prodromal Parkinson disease in the Parkinson Associated Risk Syndrome (PARS) study

    P. Vaswani, J. Morley, D. Jennings, A. Siderowf, K. Marek, P. Investigators (Philadelpiha, USA)

    Objective: To assess whether repeat olfactory testing in initially hyposmic subjects improves prediction of conversion to Parkinson disease (PD). Background: Hyposmia is a common prodromal…
  • MDS Virtual Congress 2021

    Smell dysfunction correlates with severity of motor deficits in H&Y stage-I early onset Parkinson’s disease

    J. Wang, R. Stanford, Q. Yang, L. Spreen, M. Wang, B. Mullen, K. Venkiteswaran, T. Subramanian (Hershey, USA)

    Objective: The objective of this study is to test the hypotheses that: 1) olfactory dysfunction in early stage Parkinson’s disease (PD) is correlated with severity…
  • MDS Virtual Congress 2021

    Extending the spectrum of non-motor symptoms in pre-motor Huntington’s disease – a pilot study

    B. Heim, D. Valent, F. Carbone, S. Spielberger, F. Krismer, A. Djamshidian, K. Seppi (Innsbruck, Austria)

    Objective: The aim of this pilot study was to investigate change of olfactory functions in Huntington's disease. Background: Huntington's disease (HD) is a neurodegenerative disease…
  • MDS Virtual Congress 2021

    Defining LRRK2-PD subsets based on olfactory function in the PPMI

    K. Marek, A. Siderowf, C. Tanner, T. Simuni, L. Chahine, M. Brumm, C. Coffey (New Haven, USA)

    Objective: A major goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical and biomarker defined disease subsets that may demonstrate differing disease…
  • MDS Virtual Congress 2021

    Serum uric acid as a putative biomarker in Prodromal Parkinson’s disease: Longitudinal data from the PPMI study.

    C. Koros, A-M. Simitsi, N. Papagiannakis, A. Bougea, A. Prentakis, D. Papadimitriou, I. Pachi, R. Antonelou, E. Angelopoulou, E. Efthymiopoulou, I. Beratis, M. Bozi, S. Papageorgiou, A. Bonakis, M. Stamelou, L. Stefanis (Athens, Greece)

    Objective: Our present study assessed the role of serum uric acid as a putative biomarker in a prodromal PD cohort [REM Sleep Behavior disorder (RBD)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley